3,4-Methylenedioxy-N-propylamphetamine

MDPR

Clinical data
Routes of administration	Oral
Drug class	Psychoactive drug
ATC code	None
Pharmacokinetic data
Duration of action	Unknown
Identifiers
IUPAC name N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]propan-1-amine
CAS Number	74698-36-5 Y
PubChem CID	559375
ChemSpider	486273
UNII	B4W69BKX3L
ChEMBL	ChEMBL197038
CompTox Dashboard (EPA)	DTXSID50339877
ECHA InfoCard	100.217.125
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.300 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(NCCC)Cc1ccc2OCOc2c1
InChI InChI=1S/C13H19NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h4-5,8,10,14H,3,6-7,9H2,1-2H3 Key:LBXMQBTXOLBCCA-UHFFFAOYSA-N
(verify)

3,4-Methylenedioxy-N-propylamphetamine (MDPR) is a lesser-known psychoactive drug and a substituted amphetamine. MDPR was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 200 mg, and the duration unknown. MDPR is described as a "promoter"; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH.

Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD, and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7. The reason for this synergistic action of MDPR has not been elucidated. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPR other than what is written in PiHKAL.

See also

• Substituted methylenedioxyphenethylamine
• Phenylpropylaminopentane
• Benzofuranylpropylaminopentane
• MDAL